Cancer Specialist (Oncologist), Hematology and Oncology Specialist
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of…
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor…
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2* early breast cancer with intermediate-high or high risk for disease recurrence who completed…
41 publications
2013
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
•